N Engl J Med:孕期亚临床甲减或低甲状腺素血症:是否服药治疗是个问题!

2017-04-10 王英泽 环球医学

左旋甲状腺素可由胃肠道吸收,但吸收不完全,吸收率不定,特别是在与食物同服时。2017年3月,发表在《N Engl J Med》的研究对怀孕期间被认定为患有亚临床甲状腺功能减退症或低甲状腺素血症的妇女使用左旋甲状腺素治疗是否会改善其孩子的认知功能进行了实验分析。背景:怀孕期间亚临床甲状腺疾病可能与不良结局有关,包括后代智商低于正常水平。在怀孕期间被认定为患有亚临床甲状腺功能减退症或低甲状腺素血症的妇

左旋甲状腺素可由胃肠道吸收,但吸收不完全,吸收率不定,特别是在与食物同服时。2017年3月,发表在《N Engl J Med》的研究对怀孕期间被认定为患有亚临床甲状腺功能减退症或低甲状腺素血症的妇女使用左旋甲状腺素治疗是否会改善其孩子的认知功能进行了实验分析。

背景:怀孕期间亚临床甲状腺疾病可能与不良结局有关,包括后代智商低于正常水平。在怀孕期间被认定为患有亚临床甲状腺功能减退症或低甲状腺素血症的妇女使用左旋甲状腺素治疗是否会改善其孩子的认知功能尚不明确。

方法:研究人员筛选了妊娠20周以前单胎妊娠亚临床甲状腺功能减退症及低甲状腺素血症妇女,其中亚临床甲状腺功能减退症定义为促甲状腺素水平≥4.00 mU/L和正常的游离甲状腺素(T4)水平(0.86~1.90 ng/ dL [11~24 pmol/L]);低甲状腺素血症其定义为促甲状腺素水平正常(0.08~3.99mU / L)和低游离T4水平(<0.86ng / dL)。在两种疾病的单独试验中,妇女被随机分配接受左旋甲状腺素或安慰剂。每月评估甲状腺功能,并调整左甲状腺素剂量以达到正常的促甲状腺素或游离T4水平(取决于试验),并对安慰剂进行假调整。儿童持续五年,每年进行发育和行为测试。主要结局指标是5岁时的智商分数(或在三岁时的智商分数,如果五年检查缺失的话)或年龄小于3岁死亡。

结果:共计677例亚临床甲状腺功能减退症的妇女在妊娠平均16.7周时随机化,526例低甲状腺素血症患者在妊娠平均17.8周时随机化。在亚临床甲状腺功能减退症试验中,左旋甲状腺素组儿童中位IQ评分为97(95%置信区间[CI],94至99),安慰剂组中位IQ评分为94(95%CI,92至96)(P = 0.71)。在低甲状腺素血症试验中,左旋甲状腺素组的中位IQ评分为94(95%CI,91至95),安慰剂组中位IQ评分为91(95%CI,89至93)(P = 0.30)。在每个试验中,4%的儿童缺失IQ分数。任何其他神经认知或妊娠结局或不良事件发生率在实验组间均无显着差异,两组均较低。

结局:从妊娠8至20周开始,治疗亚临床甲状腺功能减退症或低甲状腺素血症与不进行治疗相比,并不能导致儿童5岁时显着更优的认知结果。

原始出处:

Casey B M, Thom E A, Peaceman A M, et al. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. New England Journal of Medicine, 2017, 376.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081352, encodeId=41402081352f4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 03 04:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785452, encodeId=d2df1e8545242, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 20 04:08:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341302, encodeId=a34213413023c, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607377, encodeId=83e5160e377c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186537, encodeId=cee418653e8c, content=学习,临川难决策, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 11 00:26:52 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2018-02-03 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081352, encodeId=41402081352f4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 03 04:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785452, encodeId=d2df1e8545242, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 20 04:08:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341302, encodeId=a34213413023c, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607377, encodeId=83e5160e377c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186537, encodeId=cee418653e8c, content=学习,临川难决策, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 11 00:26:52 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-06-20 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081352, encodeId=41402081352f4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 03 04:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785452, encodeId=d2df1e8545242, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 20 04:08:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341302, encodeId=a34213413023c, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607377, encodeId=83e5160e377c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186537, encodeId=cee418653e8c, content=学习,临川难决策, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 11 00:26:52 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081352, encodeId=41402081352f4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 03 04:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785452, encodeId=d2df1e8545242, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 20 04:08:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341302, encodeId=a34213413023c, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607377, encodeId=83e5160e377c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186537, encodeId=cee418653e8c, content=学习,临川难决策, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 11 00:26:52 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081352, encodeId=41402081352f4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 03 04:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785452, encodeId=d2df1e8545242, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 20 04:08:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341302, encodeId=a34213413023c, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607377, encodeId=83e5160e377c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:08:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186537, encodeId=cee418653e8c, content=学习,临川难决策, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 11 00:26:52 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-04-11 wen2009

    学习,临川难决策

    0

相关资讯

Circ-Cardiovasc Inte:妊娠与自发性冠状动脉夹层的风险分析

由此可见,妊娠相关的自发性冠状动脉夹层通常与左前降支、左主干和多支血管病变相关,导致射血分数降低、危及生命的母体和胎儿的并发症发病率较高。经皮冠状动脉介入术与低成功率和并发症的高可能性相关,往往需要冠状动脉搭桥手术。因持续性或新发自发性冠状动脉夹层导致的复发性缺血性事件在长期随访中很常见。

Obstet Gynecol:计划性妊娠与孕妇酒精摄入之间有啥关系?

大多数妇女,无论有无计划性,在意识到妊娠后会停止或减少饮酒。这表明早点知道妊娠的意识可能比在所有妊娠的女性中提倡戒酒要更有效。

Obstet Gynecol:既往进行减肥手术的妇女妊娠时腹部手术的风险如何?

由此可见,减肥手术与妊娠期间腹部手术的风险增加相关。

Hypertension:妊娠的易卒中自发性高血压大鼠尿中多肽组学有啥变化?

该研究首次强调了尿调节素的潜在作用以及它在高血压妊娠中的聚合。

Am J Reprod Immunol:阿司匹林和低分子肝素通过改变滋养层功能改善病态妊娠

阿司匹林和低分子肝素通过改变滋养层功能改善病态妊娠。

Am J Kidney Dis:IgA肾病患者妊娠及肾脏结局如何?

由此可见,妊娠会加速IgAN以及CKD 3期女性肾脏疾病的进展速度,但不会加快CKD 1或2期患者肾脏疾病的进展速度。